GMAB vs HRMY Stock Comparison

GMAB currently leads HRMY in this stock comparison, with AIQ scores of 77 vs 73. The clearest difference is momentum, while HRMY has the stronger value profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 4 points
GMAB
Healthcare
vs
HRMY
Healthcare
GMAB
Genmab A/S
Leads
Price
$51.37
Day move
-0.72%
AIQ Score
77/100
Best edge
Momentum
Sector
Healthcare
HRMY
Harmony Biosciences Holdings, Inc.
Price
$33.76
Day move
-0.12%
AIQ Score
73/100
Best edge
Value
Sector
Healthcare

What is the main difference between GMAB and HRMY?

GMAB leads the current stock comparison as Genmab A/S, with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Genmab A/S vs Harmony Biosciences Holdings, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

GMAB leads

GMAB leads by 4 AIQ points, primarily on Momentum, having only recently taken the lead back from HRMY. Wall Street currently favors HRMY on target upside.

Fragile: 3 of 6 evidence groups support GMAB, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Reversed
GMAB

Genmab A/S

Leads
AIQ Score
77/100
AIQ Edge Score
10/10
HRMY

Harmony Biosciences Holdings, Inc.

AIQ Score
73/100
AIQ Edge Score
9/10

The Algovestiq AIQ Score currently favors GMAB over HRMY, 77 versus 73 as of Nov 15, 2026. GMAB's advantage is driven primarily by stronger momentum, while HRMY holds the stronger value profile. GMAB also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors HRMY. 3 of 6 covered evidence groups favor GMAB today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 4 points. GMAB lead: Reversed — HRMY led by 3 AIQ points 30 sessions ago; GMAB now leads by 4.

Compare Genmab A/S and Harmony Biosciences Holdings, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

GMAB
+20.6%
HRMY
-15.9%

Price return comparison

Growth of $10,000, price only

GMAB $12,062 · HRMY $8,413

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare GMAB and HRMY against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

GMAB advantage
0
HRMY advantage
  • Momentum94 vs 66
    GMAB +28
  • Value71 vs 89
    HRMY +18
  • Quality72 vs 77
    HRMY +5
  • Risk Resilience58 vs 63
    HRMY +5

3 of 6 evidence groups favor GMAB. GMAB’s edge is concentrated in momentum; HRMY keeps a meaningful value edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

GMAB-1 AIQ

No factor moved materially.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.57x)
HRMY0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 3 active signals are unchanged.

GMAB's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — GMAB and HRMY both carry a full feed there.

The central trade-off

GMAB (Genmab A/S): the stronger current systematic profile, led by momentum.

HRMY (Harmony Biosciences Holdings, Inc.): the counter-case, on value, quality, risk resilience.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

GMAB

GMAB on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

GMAB

GMAB on combined revenue and EPS growth.

Value

HRMY

HRMY on the peer-relative Value factor, by 18 points.

Momentum

GMAB

GMAB on the Momentum factor, by 28 points.

Lower downside

HRMY

HRMY on Risk Resilience, by 5 points.

Analyst upside

HRMY

HRMY on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors GMAB, analyst targets favor HRMY. That disagreement is the most useful thing on this page.

MeasureGMABHRMYNote
Implied upside to target+8%+52.5%HRMY has more room
Target dispersion+50.5%+35%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1312Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor GMAB. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreGMAB77 vs 73
FundamentalsGMABrevenue growth 2.8% vs 2.9%; EPS growth 14.3% vs -36.2%; TTM ROE 5.4% vs 4.5%; gross margin 92.6% vs 74%; operating margin 30.5% vs 22.2%
ValuationHRMYValue 71 vs 89
TechnicalsGMABPrice vs 50-day 24.8% vs -12.6%; vs 200-day 62.9% vs -2.4%
Risk ResilienceHRMYRisk Resilience 58 vs 63
Analyst expectationsHRMYTarget upside 8% vs 52.5%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of GMAB and HRMY and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 4 points. (argues the conclusion is provisional)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on GMAB.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

GMAB lead: Reversed — HRMY led by 3 AIQ points 30 sessions ago; GMAB now leads by 4.

May 27GMAB leads above the line · HRMY leads belowNov 13
Today
GMAB +4
77 vs 73
7 sessions ago
GMAB +3
79 vs 76
30 sessions ago
HRMY +3
77 vs 80
90 sessions ago
HRMY +6
68 vs 74

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

GMABConflicted

3 bullish / 3 bearish / 1 neutral, conflicted

Only GMAB

  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.57x)
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • RSI Bearish Divergence — bearish, momentum, medium horizon
  • Uptrend Structure Active — bullish, trend, long horizon
HRMY

1 bullish / 0 bearish / 2 neutral

Only HRMY

  • ADX Trend Strengthening — neutral, trend, medium horizon

Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.

GMAB leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

GMABConfirmed weakness

Price and the AIQ Score both moved down over the latest session (price -0.72%, AIQ -1 points).

HRMYNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.12%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1HRMY closes the Momentum gap — currently 28 points behind, the largest single contributor to GMAB's edge.
  2. 2HRMY's ADX Trend Strengthening turns directional — it is neutral today and would confirm a change in trend.
  3. 3GMAB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

GMAB leads on balance
MetricGMABHRMY
Revenue growth (YoY)2.8%2.9%
EPS growth (YoY)14.3%-36.2%
Gross margin92.6%74%
Operating margin30.5%22.2%
Return on equity (TTM)5.4%4.5%
Debt to equity0.820.14

Performance

GMAB leads 5 of 6 windows
MetricGMABHRMY
1 week (5 sessions)-4.2%2%
1 month (20 sessions)38.8%-11%
3 months (63 sessions)56.4%-11.5%
6 months (126 sessions)93.6%12.2%
Year to date66.8%-9.8%
1 year (252 sessions)68.6%0.7%

Technicals

GMAB has the stronger structure
MetricGMABHRMY
RSI (14)59.136.4
ADX (14)45.834.7
Price vs 50-day24.8%-12.6%
Price vs 200-day62.9%-2.4%
Volatility (1M, annualized)110.9%46.4%

Risk

HRMY is the more resilient
MetricGMABHRMY
Beta0.930.63
Sharpe ratio1.290.07
Sortino ratio2.530.09
Max drawdown-32.5%-34.5%
Current drawdown-10.3%-21.2%
Annualized volatility45.9%40.6%
Value at risk (95%)-3.2%-3.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, GMAB or HRMY?

On the Algovestiq AIQ Score, GMAB is the stronger of the two as of Nov 15, 2026, scoring 77 against HRMY's 73. The edge comes from momentum. HRMY is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is GMAB or HRMY the better buy right now?

GMAB carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 4 points. Treat the lead as provisional.

Why does the AIQ Score favor GMAB over HRMY?

The composite weights Quality, Value, Momentum and Risk Resilience. GMAB leads Momentum by 28 points; HRMY leads Value by 18 points; HRMY leads Quality by 5 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, GMAB or HRMY?

Analyst price targets imply +8% upside for GMAB and +52.5% for HRMY, so the Street currently favors HRMY. That points the opposite way to the AIQ Score, which favors GMAB. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, GMAB or HRMY?

HRMY is the better-valued of the two on the peer-relative Value factor. HRMY on the peer-relative Value factor, by 18 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, GMAB or HRMY?

GMAB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, GMAB or HRMY?

GMAB on the Momentum factor, by 28 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, GMAB or HRMY?

HRMY is the more resilient of the two, so the other name carries the higher downside risk. HRMY on Risk Resilience, by 5 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is GMAB more profitable than HRMY?

GMAB leads on the comparable margin measures — gross margin 92.6% vs 74%; operating margin 30.5% vs 22.2%; ttm roe 5.4% vs 4.5%.

Is GMAB's lead over HRMY getting stronger or weaker?

GMAB lead: Reversed — HRMY led by 3 AIQ points 30 sessions ago; GMAB now leads by 4. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the GMAB vs HRMY verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: HRMY closes the Momentum gap — currently 28 points behind, the largest single contributor to GMAB's edge; HRMY's ADX Trend Strengthening turns directional — it is neutral today and would confirm a change in trend; GMAB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about GMAB and HRMY?

GMAB: 3 bullish / 3 bearish / 1 neutral, conflicted. HRMY: 1 bullish / 0 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on GMAB is Golden Cross Active (bullish, long horizon). On HRMY it is Golden Cross Active (bullish, long horizon).

Compare GMAB and HRMY with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.